Category

Lundbeckfonden Ventures
93% of patients had full or partial cyst resolution at 12 months. No post-operative infections reported during follow-up period. No fractures reported during the follow-up period
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.
Ness Ziona, Israel - Dec 7, 2015 - Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known...
Envarsus® XR is Indicated for Patients Converted from Tacrolimus Immediate-release FormulationsVeloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. launch of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from immediate release tacrolimus products to once-daily Envarsus® XR. 
Cambridge, UK - 3rd December 2015: Acacia Pharma Group plc (Acacia Pharma"), the supportive care company developing products for US and international markets, today announces that Ian Kent will retire as non-executive Chairman on 31st December 2015 and will be succeeded by Dr Patrick Vink."
Helsinki, 3 December 2015 at 9:30 amRecruitment completed ahead of scheduleNexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that it has successfully completed enrolment of its Phase III NICHE (Navigated Inhibitory rTMS to Contralesional Hemisphere) clinical trial in stroke therapy,...
Paris, France - November 12, 2015 - Enterome Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on the gut microbiome, announces that it has entered into a collaborative development agreement with Gustave Roussy, Europe's first comprehensive cancer centre.
Program aims to develop a new method of delivering trusted antibiotic without risk or costs associated with daily intravenous infusions.LEXINGTON, Mass., November 10, 2015 /PRNewswire/ -- scPharmaceuticals, Inc., announced today that it has commenced its pivotal trial of subcutaneous administration of the antibiotic ceftriaxone for use with the sc2Wear Patch Pump.  
Complete (100%) bioavailability after subcutaneous administration when compared with intravenous administration - Diuresis at 8 and 24 hours was equivalent to diuresis following standard intravenous administration - U.S. and EU regulatory filings anticipated in 2016 -LEXINGTON, MA. - scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics phase 3 pivotal registration trial.  The trial in...
GAITHERSBURG, Md., Oct. 22, 2015 /PRNewswire/ -- Vtesse, Inc. announced today the addition of Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences and Biochemistry at Rush University Medical Center to its Scientific Advisory Board (SAB) and that Michael Massaro has joined the company as Vice President, Clinical Operations. Today's news comes on the heels of Vtesse's...
1 2 3 5